Bayer Sheds 2.3% in a Weak Frankfurt Tape as Kerendia's New US Label and a $7.25 Billion Roundup Deal Pull the Story in Opposite Directions
Published on 09/19/2026 at 22:30 | Editorial boerse-global.de
Bayer shares closed Friday at EUR 47.96, down 2.3%, as a broad sell-off swept the Frankfurt floor on the final trading session of the week. There was no company-specific trigger behind the retreat. Instead, the DAX itself gave up 1.6% under the weight of Middle East geopolitical friction, firmer crude prices and rising bond yields, which dulled the appeal of equities relative to fixed income. The pullback interrupted Bayer's prior recovery rather than reflecting any fresh operational setback.
For the Leverkusen-based agriculture and pharmaceuticals group, the market's attention remains split between two very different clocks: the steady drumbeat of pipeline and cost news, and the slow grind of litigation inherited from the Monsanto acquisition.
A settlement that could close tens of thousands of cases
The legal overhang continues to shape how investors view the stock. A proposed USD 7.25 billion settlement could resolve tens of thousands of claims tied to Roundup, the glyphosate-based weedkiller, with Bayer exposed through its Monsanto subsidiary. A ruling from the Missouri court on whether to approve that deal is not expected before late September or October 2026. Until then, the uncertainty keeps a lid on sentiment, since the final enforceability of such settlement structures will determine the group's future financial headroom.
Kerendia widens its label, FIND-CKD hits its mark
Away from the courtroom, Bayer's pharmaceutical pipeline has been delivering. On Thursday, US regulators granted Kerendia approval for treating adults with chronic kidney disease and type 1 diabetes, broadening the product's reach. The same active ingredient also met its primary endpoint in the Phase III FIND-CKD trial in hypertensive nephropathy, and it already holds a European Union authorization for heart failure.
Should investors sell immediately? Or is it worth buying Bayer?
Crop Science, meanwhile, is doing the heavy lifting on the earnings side. In the second quarter of 2026, the agricultural division underpinned the group's results, and management used an investor day earlier this month to unveil new products for the unit. Cost discipline is reinforcing that push: savings realized in the division so far total nearly EUR 400 million.
Apollo's EUR 3 billion and a trimmed debt target
Balance-sheet relief arrived more than a month ago through the partnership with Apollo Global Management. The EUR 3 billion equity injection prompted management to lower its full-year net financial debt guidance to EUR 29 billion to EUR 30 billion.
The group also drew a measure of administrative attention on Friday with a mandatory notification of voting rights under German securities trading law.
Analysts keep their targets well above the market price
Despite the recent softness, sell-side opinion on the DAX member remains largely constructive. Deutsche Bank Research reaffirmed its Buy rating on September 10 with a price target of EUR 60. UBS had already taken the same stance on September 1, rating the stock Buy with a EUR 62 target.
Even after Friday's decline, Bayer's shares are up 30% since the start of the year — a gain that explains why optimists are willing to look past the remaining US litigation risk and focus instead on the gradual effect of the cost cuts and the new products in the core divisions.
Third-quarter figures are due on November 3, 2026. Between now and then, the trajectory of the US settlement proceedings is likely to be the single biggest driver of investor mood.
Ad
Bayer Stock: New Analysis - 19 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
